One of the most recent of Rensselaer's research centers is the Center for Biotechnology and Interdisciplinary Studies, a 218,000 square-foot research facility and a national pacesetter for fundamental and applied research in biotechnology. The primary target of the research center is biologics, a research priority based on data-driven understanding of proteomics, protein regulation, and gene regulation. It involves using biocatalysis and synthetic biology tools to block or supplement the actions of specific cells or proteins in the immune system. Over the past decade, CBIS has produced over 2,000 peer-reviewed publications with over 30,000 citations and currently employs over 200 scientists and engineers. The center is also used primarily to train undergraduate and graduate students, with over 1,000 undergraduates and 200 doctoral students trained. The center also has numerous academic and industry partners including the Icahn School of Medicine at Mount Sinai. These partnerships have resulted in numerous advances over the last decade through new commercial developments in diagnostics, therapeutics, medical devices, and regenerative medicine which are a direct result of research at the center. Examples of advancements include the creation of synthetic heparin, antimicrobial coatings, detoxification chemotherapy, on-demand bio-medicine, implantable sensors, and 3D cellular array chips.